Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer
PHASE1CompletedINTERVENTIONAL
Enrollment
37
Participants
Timeline
Start Date
June 18, 2020
Primary Completion Date
July 27, 2023
Study Completion Date
July 27, 2023
Conditions
Recurrent Lung Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8